Liver cancer treatment after immunotherapy
Part of Cancer clinical trials.
This trial tests a new procedure called IRE (a way to destroy tumors) for people with liver cancer that has not responded well to initial immunotherapy. It aims to help when surgery is not possible due to the tumor's size or location.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 18 and 75 years old.
- You must have liver cancer that is confirmed by imaging or biopsy.
- You cannot have had prior immunotherapy or other systemic treatments for your cancer.
- Your tumor must be 5 cm or smaller, and you can have up to 5 tumors.
- The cancer must not have spread outside the liver, except for a specific type of blood clot in the liver's main vein.
- You must be in generally good health, with adequate liver, kidney, and blood cell function.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination treatment for advanced liver cancer that cannot be removed with surgery. It combines a procedure (irreversible electroporation) that uses electrical pulses to destroy cancer cells, with targeted therapy (lenvatinib) and immunotherapy (sintilimab) to help your immune system fight the cancer.
This trial tests a combination of local treatments (like TACE or HAIC) with bevacizumab and an immunotherapy drug (PD-1/L1 inhibitor) for advanced liver cancer. It may be an option if you haven't had systemic therapy before or if your previous treatment stopped working.
This Phase 2 trial studies whether a combination of SBRT (focused radiation) plus tislelizumab and regorafenib can control unresectable or limited-spread liver cancer. It may help by attacking tumors in the liver and immune system to improve shrinkage and control of disease.
This trial tests a combination of liver-directed radiation therapy, an immunotherapy drug (which helps your immune system fight cancer), and a drug that blocks blood vessel growth to the tumor. It is for people with advanced liver cancer that cannot be treated with surgery.
This trial is collecting information on how well a treatment (likely TACE, a procedure to block the tumor's blood supply) works for people with liver cancer that cannot be removed by surgery. It aims to see how safe and effective it is for patients who haven't had treatment before or who have a first recurrence.
This trial tests a combination of treatments before and after surgery for liver cancer that can be removed. The goal is to see if adding targeted therapy and immunotherapy can reduce the risk of cancer coming back.
Hear when a new IRE trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.